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Abstract: Matrix metalloproteinase 19 (MMP-19) is a member of the MMP family of endopeptidases that, in 
contrast to most MMPs, is widely expressed in human tissues under normal quiescent conditions. MMP-19 has 
been found to be associated with ovulation and angiogenic processes and is deregulated in diverse pathological 
conditions such as rheumatoid arthritis and cancer. To gain further insights into the in vivo functions of this 
protease, we have generated mutant mice deficient in Mmp19. These mice are viable and fertile and do not 
display any obvious abnormalities. However, Mmp19-null mice develop a diet-induced obesity due to adipocyte 
hypertrophy and exhibit decreased susceptibility to skin tumors induced by chemical carcinogens. Based on 
these results, we suggest that this enzyme plays an in vivo role in some of the tissue remodeling events 
associated with adipogenesis, as well as in pathological processes such as tumor progression. 
 
The matrix metalloproteinases (MMPs) are a group of zinc-dependent endopeptidases that play major roles in the 
connective tissue remodeling occurring in a variety of physiological conditions such as embryonic growth and 
development, angiogenesis and wound healing (5, 28, 40). In addition, deregulated production of these enzymes 
is associated with multiple pathological conditions, including rheumatoid arthritis (19), atherosclerosis (13), and 
tumor invasion and metastasis (11, 12). The human MMP family is composed of more than 20 different 
members that can be classified into different subfamilies according to their primary structures, domain 
organization, cellular localization, and substrate specificity (5, 28). 
As part of our studies focused on the structural and functional characterization of this protein family, we have 
recently cloned a new human MMP that has been designated MMP-19 (32). This protease shows the archetypal 
domain organization of soluble MMPs, including a signal sequence, a propeptide with the cysteine residue 
essential for maintaining latency, a catalytic domain with the typical zinc-binding motif, a linker region, and a C-
terminal fragment with sequence similarity to hemopexin (32). However, MMP-19 lacks several structural 
features distinctive of the diverse MMP subfamilies and possesses a unique insertion of glutamic acid residues 
within the linker region. It also exhibits an unusual latency motif in the propeptide domain, an additional 
cysteine residue in the catalytic region, and a C-terminal extension lacking sequence similarity to equivalent 
regions in other human MMPs (7, 32, 41). MMP-19 is widely distributed in human tissues, which is also a 
distinctive feature of this MMP, because most family members are not frequently produced by adult cells under 
normal quiescent conditions. Accordingly, we and others have suggested that this enzyme could play a role in 
some of the normal matrix remodeling processes that take place in tissues with the ability to produce MMP-19 
(27, 32). Biochemical studies have revealed that MMP-19 shows a potent basement membrane-degrading 
activity and is also capable of degrading two components of cartilage, namely, cartilage oligomeric matrix 
protein and aggrecan (38, 39). Interestingly, MMP-19 has also been identified as an autoantigen in patients with 
rheumatoid arthritis (36), and recent studies have suggested a role for this enzyme in angiogenic processes (18). 
Therefore, according to its unique structural features and tissue distribution, MMP-19 could represent the first 
member of a new subfamily of MMPs with a critical and novel role in physiological or pathological conditions. 
To try to uncover the function of this protease, we have generated mutant mice lacking Mmp19. These mice are 
viable and fertile and do not show any overt phenotype. However, after a series of different experimental 
challenges performed on wild-type and mutant mice, we provide evidence that Mmp19-null mice develop a diet-
induced obesity and exhibit decreased susceptibility to skin tumors induced by chemical carcinogens. Based on 
these results, we suggest that this enzyme plays an in vivo role in some of the tissue remodeling events 
associated with adipogenesis and tumor progression. 
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MATERIALS AND METHODS 
Targeting vector construction.  
A genomic DNA clone was isolated from a mouse 129-SV/J genomic DNA library (Stratagene, La Jolla, Calif.) 
by using a murine Mmp19 cDNA fragment as probe. The genomic organization was determined by restriction 
analysis and subsequent subcloning of these fragments into pBluescript or pUC18. The genomic region 
immediately surrounding the first exon was sequenced and showed characteristic elements of a typical MMP 
promoter region such as an AP-1 site and a TATA box (31). Plasmid pPN2T-Hgterm (kindly provided by C. 
Paszty, Lawrence Berkeley National Laboratory, Berkeley, Calif.) containing the pgk-neo and two pgk-tk 
(thymidine kinase) selection markers was used to construct the Mmp19 targeting vector. A 1.6-kb EcoRI-BamHI 
fragment from the 5'-flanking region was used as the 5'-homol-ogous region, whereas a 6-kb Xhol-Notl fragment 
containing exons 3 to 8 was used as the 3'-region of homology. The 2.4-kb neo cassette was used as a positive 
marker and replaced a 3-kb fragment containing 1 kb of promoter and exons 1 and 2 of the gene (Fig. 1A). After 
both fragments were cloned, the BamHI restriction site of the short arm was destroyed by digestion and blunt-
ended religation to further generate a BamHI RFLP in the targeted allele. 
FIG. 1: Targeted disruption of mouse Mmp19 gene. (A) Restriction maps of the Mmp19 gene region of interest (top), the 
targeting construct (center), and the mutant locus after homologous recombination (bottom). B, BamHI; B with superimposed X, destroyed 
BamHI; H, HindIII; P, PstI; RI, EcoRI; RV, EcoRV. (B) BamHI Southern blot analysis of +/+, +/-, and -/- mice. (C) Detection of Mmp19 
mRNA in the liver, lung, and ovary by Northern blot analysis. 
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Generation of Mmp19-null mice.  
The targeting vector was linearized by digestion with NotI, electroporated into HM-1 embryonic stem (ES) cells, 
and selected for homologous recombination with G418 and ganciclovir. Positive clones were screened by 
Southern blot after BamHI digestion of genomic DNA and probed with a radiolabeled 5'-external probe (Fig. 
1B). A 3-kb fragment was detected from the wild-type allele and a 9-kb fragment from the mutant allele. The 
targeted ES cell clones were expanded and subsequently injected into blastocysts to generate chimeras. Chimeric 
males were mated with black female mice and the offspring heterozygous for Mmp19+/- were used to generate 
homozygous null mice. Mice genotypes were determined by Southern blot analysis of tail DNA.  
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Northern blot analysis.  
Total RNA from frozen subcutaneous (SC) and gonadal (GON) adipose tissue was isolated by using a 
commercial kit (RNeasy Mini Kit; Qiagen). A total of 10 µg of denatured RNA was resolved by electrophoresis 
on 1.2% agarose gels and transferred to Hybond N+ (Anersham Pharmacia Biotech). Blots were hybridized with 
random primed 32P-labeled cDNA probes for mouse Mmp19 (AAF73292), Ppary, Serbp1, leptin, and Mrp2. 
Probes were obtained by using reverse transcriptase PCR from adipose tissue RNA. The following sets of 
primers were used for PCR amplification: Pparγ (GenBank accession number NM_011146; forward, 5'-
CCGAAGAACCATCC GATTGAAG-3', reverse, 5'-AAAAATTCGGATGGCCACCTCT-3'), Serbp1 
(GenBank accession number AF374266; forward, 5'-TTCTCTGGCCTCCTCT CTGGAA-3'; reverse, 5'-
AGACCGGTAGCGCTTCTCAATG-3'),leptin (GenBank accession number M96827; forward, 5'-
AGCACTTGGTTCGCTATCGC T-3'; reverse, 5'-TTCCCCACGTAGAGCGTTAGG-3'), and Mrp2 (GenBank 
accession number U15209; forward, 5'-TCATACTGCCCTCTCCTTCCTC-3': reverse, 5'-
CTCCAGACCTTGCCCATTTATC-3'). Blots were rehybridized with a β-actin cDNA probe as an indicator of 
RNA loading. 
High-fat diet treatment.  
Four-week-old Mmp19-deficient and wild-type mice (C57BL/6/12901a mixed genetic background) were kept in 
microisolation cages on a 12-h day-night cycle and fed a high-fat diet containing 42% fat (Harlan TD 88137; 
Zeiss). Mice were weighted twice a week for the first 15 weeks and once a week for the rest of the experiment. 
After 30 weeks, the mice were sacrificed by cervical dislocation. SC and GON fat pads were removed, and the 
wet weight was determined. Portions of the adipose tissues were immediately frozen at -80°C for RNA or 
protein extraction or fixed in 4% paraformaldehyde for histology. Pieces of the skin were dissected from the 
same region of the back and processed for histological analysis. 
Zymography.  
Frozen SC and GON adipose tissue were incubated overnight at 4°C on a table rocker in 10 mM sodium 
phosphate buffer (pH 7.2) containing 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 
0.5% sodium deoxycholate, and 0.2% NaN3. After centrifugation, the protein concentration of the supernatant 
was evaluated by bicinchoninic acid technique (BCA Protein Assay kit; Pierce). Then, 18 µg of nonreduced 
protein sample was loaded on 8% SDS-polyacrylamide gels containing 0.2% gelatin. After electrophoresis, 
proteins were renatured by incubating gels in 2.5% Triton X-100 for 3 h at room temperature. Gels were then 
washed twice in water and incubated overnight at 37°C in substrate buffer (20 mM Tris [pH 7.4], 5 mM CaCl2). 
Gels were stained with 0.25% Coomassie blue and destained in 7.5% acetic acid. 
TABLE 1: Effect of Mmp19-/- deficiency on adipose tissue weight and cellularity after 30 weeks of high-fat diet 
 Mean = SEM ina: 
Measurement Males Females 
 Mmp19+/+ Mmp19-/- Mmp19+/+ Mmp19-/- 
SC fat pad (mg) 706 ± 73 1,947 ± 271* 274 ± 38 866 ± 118** 
GON fat pad (mg) 1,249 ± 156 1,912 ± 228 80 ±22 491 ± 79** 
SC adipocyte surface (µm2) 1,193 ± 60 1,937 ± 641 985 ± 20 3,032 ± 264** 
GON adipocyte surface (µm2) 2,472 ± 199 2,202 ± 617 1,135 ± 81 3,040 ± 551* 
Skin adipocyte surface (µm2) 1,350 ± 186 1,885 ± 545* 781 ± 51 2,141 ± 435* 
SC adipocyte no. (cells/mm2) 666 ± 33 308 ± 40** 825 ± 50 376 ± 58** 
GON adipocyte no. (cells/mm2) 331 ± 39 293 ± 25 706 ± 39 328 ± 19** 
Skin adipocyte no. (cells/mm2) 562 ± 60 315 ± 39* 842 ± 64 487 ± 31* 
a *, P < 0.05; **, P < 0.01 (versus the corresponding wild-type mice). 
Histological analysis.  
Tissues were fixed in 4% paraformaldehyde in phosphate-buffered saline and stored in 70% ethanol. Fixed 
tissues were embedded in paraffin by standard procedures. Blocks were sectioned (5 µm) and stained with 
hematoxylin and eosin. For adipose tissue evaluation, portions of GON and SC fat pads and pieces of skin were 
processed as described above. The SC fat pad represented the adipose tissue overlaying the posterior iliac crest 
and was dissected from its attachment sites to the skin. The number of adipocytes and their mean diameter were 
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determined in 3-µm tissue sections by computer-assisted image analysis. For each sample, different sections 
were analyzed, and 100 adipocytes were measured. The area of the cells was calculated considering the 
maximum and minimum diameter of each adipocyte. 
Carcinogenesis protocols and analysis of tumors.  
Mouse experimentation was done in accordance with the guidelines of the Universidad de Oviedo regarding the 
care and use of laboratory animals. For methylcholanthrene (MCA) chemical carcinogenesis, groups of Mmp19-/- 
(n = 11) and wild-type (n = 12) male mice were injected SC with a freshly prepared solution of MCA in olive oil 
(100 µg in 100 µl per mouse) in each flank. We observed mice weekly for tumor development over the course of 
22 to 30 weeks. Tumors larger than 5 mm and showing progressive growth were counted as positive and 
confirmed thereafter by histological analysis. Mice were killed when they had an overt tumor mass or if they 
looked moribund. After conventional staining with hematoxylin and eosin, cells were morphologically identified 
by an expert pathologist and counted with no previous knowledge of mouse genotype and time point in each 
slide. 
Preparation of the three-dimensional aortic ring cultures.  
Angiogenesis was studied by culturing rings of mouse thoracic aorta in three-dimensional collagen gels as 
previously described (26). Briefly, 1-mm-long aortic ring-shaped fragments were embedded in a rat tail 
interstitial collagen gel (1.5 mg/ml) (3) prepared by mixing 7.5 volumes of 2 mg of collagen/ml (Collagen R; 
Serva, Heidelberg, Germany), 1 volume of 10x minimum essential medium (Life Technologies, Ltd., Paisley, 
Scotland), 1.5 volumes of NaHCO3 (15.6 mg/ml), and 0.1 volume 1 M NaOH to adjust the pH to 7.4. The 
collagen gels containing the aortic rings were polymerized in cylindrical agarose wells and kept in triplicate at 
37°C in 60-mm-diameter petri dishes (bacteriological polystyrene; Falcon; Bee-ton Dickinson, Lincoln Park, 
N.J.). Each dish contained 6 ml of MCDB131 (Life Technologies, Ltd.) supplemented with 25 mM NaHCO3, 
2.5% mouse serum, 1% glutamine, 100 U of penicillin/ml, and 100 µg of streptomycin/ml. The cultures were 
kept at 37°C in a humidified environment for a week and examined every second day with an Olympus 
microscope at appropriate magnifications. Results were drawn from three independent assays performed in 
triplicate. 
Quantification of angiogenesis.  
Image analysis was performed on a Sun SPARC30 work station with the software Visilog 5.0 from Noesis. We 
used an improved computer-assisted image analysis (3, 10) that allows automatic measurements of the 
geometrical and morphological parameters. After generation of binary image, the following automatic 
measurements were obtained: the number of microvessels (Nv), the maximal microvessel length (Lmax), and the 
total number of branches in microvessels (Nb). 
Statistical analysis.  
All experimental data are reported as means ± the standard errors of the mean, and statistical analysis was 
performed by using the nonparametric Student t test. 
RESULTS 
Generation of Mmp19-deficient mice.  
To examine the in vivo function of Mmp19, we generated mice with a targeted mutation in the Mmp19 gene. A 
genomic clone encoding Mmp19 was obtained from a mouse 129-SV/J genomic DNA library and used for 
construction of the targeting vector (Fig. 1A). This vector was designed to allow the replacement of the promoter 
region and exons 1 and 2 of the endogenous Mmp19 gene with a neo cassette (Fig. 1A). The linearized targeting 
vector was electroporated into HM-1 ES cells, and 10 clones that were positive for homologous recombination 
were used to generate chimeric founder mice. Heterozygous mice from the F1 generation were identified by 
Southern blot analysis and then crossed to obtain Mmp19-null mice (Fig. 1B). Northern blot analysis of total 
RNA from diverse tissues of wild-type and knockout animals revealed that the Mmp19 transcript was absent in 
homozygous null mice (Fig. 1C). The same negative results were obtained by RT-PCR of these tissues (data not 
shown), confirming the generation of an Mmp19-null allele. 
Despite the Mmp19 deficiency, these mutant mice developed normally, with males and females being fertile. 
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Likewise, there were no gross detectable differences between the growth curves of wild-type and knockout mice. 
In addition, the mutant mice showed no overt phenotype, and their long-term survival rates were 
indistinguishable from those of their wild-type littermates. Finally, histopathologic analysis of diverse tissues in 
adult Mmp19-/- animals revealed no observable differences with wild-type tissues (data not shown). Taken 
together, these data demonstrate that Mmp19 is dispensable for embryonic and adult mouse development, as well 
as for normal growth and fertility, possibly due to functional redundancy with other members of the MMP 
family.  
FIG. 3: Increased body weight and adipocyte hypertrophy in Mmp19-/- mice after 30 weeks of a high-fat diet. (A) 
Photographs of representative Mmp19-/- and Mmp19+/+ mice. (B) Hematoxylin and eosin staining of skin, SC, 
and GON adipose tissue sections taken from Mmp19-/-and Mmp19+/+ mice. 
 
Nutritionally induced obesity in Mmp19-null mice.  
In the course of characterization of Mmp19-deficient mice, we noticed an increase in the body weight of aged 
mice that was not observed in the wild-type mice kept on standard chow. This observation prompted us to 
evaluate the possible role of Mmp19 in adipose tissue biology. To this aim, wild-type and Mmp19-null mice 
were fed a high-fat diet. At the start of the study (4-week-old mice), the body weight of Mmp19-/- mice was 
slightly higher (17.7 ± 0.8 g, n = 11) than that of wild-type animals (16.3 ± 0.8, n = 16), but this difference was 
not statistically significant. However, after 30 weeks on this high-fat diet, the body weight of the Mmp19-/- mice 
was significantly higher than that of the controls (44.9 ± 4.0 g versus 34.8 ± 2.4 g; P < 0.05). When the growth 
curves were analyzed with respect to the sex of the mice (Fig. 2), there was a pronounced gain of weight in both 
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Mmp19-/- male and female mice compared to the corresponding groups of male and female controls (38.7 ± 4.0 
versus 26.2 ± 1.6 [P < 0.04] and 19.6 ± 2.5 versus 11.3 ± 1.0 [P < 0.02]). 
To determine whether the increase in body weight observed in Mmp19-deficient mice was due to an increase in 
fat content, SC and GON fat pad deposits were separately weighted. As shown in Table 1, the total weight of 
both fat pads was also higher in the Mmp19-/- than in the wild-type controls, except for the GON fat deposits in 
the male mutants. Analysis of cellularity of the SC and GON fat pads by hematoxylin-eosin staining and 
morphometric measurement of adipocyte diameters revealed that the surfaces of SC, GON, and skin adipocytes 
from Mmp19-null male and female mice were bigger than those of the controls except for the GON fat pad from 
mutant male mice (Table 1 and Fig. 3). The number of adipocytes per surface unit was lower in Mmp19-deficient 
mice. Taken together, these results indicate that the observed diet-induced obesity in Mmpl 9-deficient mice is 
linked to a marked hypertrophy of the adipocytes of these mice compared to their wild-type controls. We next 
tried to determine whether the observed adipocyte hypertrophy in Mmp19 mutant mice is due to an alteration of 
the adipocyte differentiation program. To test this possibility, we compared by Northern blot analysis the 
expression of key adipocyte regulators, including Pparγ, leptin, Srebpl, and Mrp2, in GON and SC fat pads of 
Mmp19-/- and wild-type mice kept on a high-fat diet. Despite the fact that these genes have been shown to be 
involved in various steps of adipogenesis (17, 23, 33), we were unable to detect any significant differences in 
their expression levels in Mmp19-/- mice (Fig. 4). 
FIG. 4: Expression analysis of Pparγ, leptin, Srebpl, and Mrp2 in Mmp19-/- and wild-type mice. RNA was 
prepared from GON and SC adipose tissues of three representative mice kept on a high-fat diet and analyzed by 
Northern blotting. 
 
On the other hand, it has been recently reported that Mmp2 is the main gelatinase expressed within adipocyte 
tissue (25). To gain further insight into a possible differential activity of this gelatinolytic system in the absence 
of the Mmp19, we analyzed GON and SC adipose tissues from Mmp19-/- and wild-type mice by gelatin 
zymography. However, similar gelatinolytic activities for proMmp2 and Mmp2 were detected in both types of 
mice (not shown), indicating that the absence of Mmp19 is not compensated for by an increase in the activity of 
the major adipocyte gelatinase. 
Mmp19-deficient mice are more resistant to the development of MCA-induced fibrosarcomas.  
MMP-19 has been detected in dermal fibroblasts and keratinocytes of human skin, as well as in inflammatory 
cells such as monocytes and macrophages, suggesting a role for this protease in inflammatory processes and skin 
tumorigenesis (14, 35). To evaluate this possibility, wild-type and Mmp19 mutant male mice were subjected to a 
skin carcinogenesis protocol based on the intradermal injection of a single dose of the chemical carcinogen 
MCA. As shown in Fig. 5A, fibrosarcomas arose more rapidly and with a significantly higher incidence in wild-
type mice than in Mmp19-deficient mice. These differences in the number of fibrosarcomas between mutant 
mice and wild-type controls were statistically significant (P < 0.05). Histological analysis of the fibrosarcomas 
generated in both wild-type and Mmp19-/-male mice revealed that most of them (80%) were undifferentiated and 
invasive grade III fibrosarcomas (Fig. 5B), suggesting that the absence of Mmp19 does not influence the late 
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stages of tumor development in male mice. In addition, Northern blot analysis of MCA-induced fibrosarcomas in 
wild-type mice revealed a high level of expression of Mmp19 in these malignant tumors (data not shown), 
reflecting its putative relevance in the carcinogenesis process. 
To evaluate the possibility that reduced tumor susceptibility in mutant mice could be due to angiogenesis 
deficiencies derived from the absence of this protease, we compared this process in knockout and wild-type 
animals by using a quantitative angiogenesis model. Segments of mouse thoracic aortas embedded in a collagen 
gel were cultured in MCDB131 medium containing autologous serum (2.5% final concentration). During the 
first 4 days of culture, isolated fibroblast-like cells migrated into the gel. Subsequently, microvessel outgrowths 
arose from the edges of the parental vessel where the basement membrane had been ruptured. As shown in Fig. 
6, no differences were observed in the number of microvessels (Nv, 7 ± 4 versus 7 ± 5), the number of branchings 
(Nb, 14.5 ± 7 versus 15 ± 7), and the length of the vessels (Lmax, 1.12 ± 0.4 mm versus 1.04 ± 0.32 mm) between 
mutant and wild-type mice, respectively. The angiogenic response in the mice aortic ring assay was not 
dependent on the presence or absence of Mmp19, indicating that this protease does not play a critical role in 
angiogenesis in this experimental model. 
DISCUSSION 
We describe here the generation and phenotype analysis of mutant mice deficient in Mmp19, a member of the 
MMP family of endopeptidases with a wide tissue-distribution and a series of structural and enzymatic 
characteristics that do not allow its classification in any of the well-established MMP subfamilies, including 
collagenases, stromelysins, gelatinases, and membrane-type MMPs. However, and despite the wide expression 
pattern of Mmp19 under normal quiescent conditions, targeted disruption of this gene in mice does not cause any 
major abnormalities. Thus, and similar to most cases of mice deficient in single specific MMPs, Mmp19-null 
mice develop normally, are fertile, and have long-term survival rates indistinguishable from those of wild-type 
mice. Nevertheless, further analysis of Mmp19-/- mice subjected to diverse challenges has allowed us to uncover 
the involvement of this enzyme in different normal and pathological processes. Our first studies in this regard 
were derived from the observation that aged mutant mice exhibited an increase in body weight compared to 
control littermates. These differences were significantly enhanced when mice were fed a high-fat diet, suggesting 
that Mmp19 could be somewhat involved in regulating adipogenesis, as reported for other proteases of different 
catalytic classes (15, 16, 20, 29, 37). Histopathologic analysis revealed that the increased body weight observed 
in Mmp19-null mice is due to an overall increase in both SC and GON fat pad deposits, which in turn is caused 
by a marked adipocyte hypertrophy in these mice compared to their wild-type controls. Taken together, these 
findings indicate that Mmp19 is a negative regulator of adipose tissue formation. 
The role of MMPs in adipose tissue remodeling has been demonstrated in several studies, but most of these 
studies have concluded that MMPs are positive regulators of this process (4, 6, 9, 21, 25). Thus, several studies 
have independently shown that treatment of preadipocyte cell lines with synthetic MMP inhibitors blocks the 
adipocyte differentiation process (4, 9, 25). Likewise, treatment with MMP inhibitors impairs adipose tissue 
development in mice fed a high-fat diet (21). Furthermore, the secretion of MMP-2 and MMP-9 increases during 
adipocyte differentiation in both human adipocytes and mouse preadipocyte cell lines, suggesting that these 
Mmps contribute to adipogenesis by promoting adipocyte differentiation (4, 6, 25). However, there are at least 
two additional MMPs that appear to play inhibitory roles in adipogenesis that are similar to those here reported 
for Mmp19. Mice deficient for Mmp3 show accelerated adipogenesis during mammary gland involution and 
enhanced diet-induced adipose tissue development (1, 24), whereas Mmp11-null mice display a nutritionally 
induced obesity whose molecular basis has not been reported yet (22). Likewise, at present we can only 
speculate about the potential role of Mmp19 as a negative regulator of adipogenesis. Thus, the wide substrate 
specificity of Mmp19 could facilitate the degradation of different extracellular matrix components that could 
provide inhibitory signals to adipocytes. The recent finding that Mmp19 is also upregulated in obese adipose 
tissue and during differentiation of 3T3-L1 preadipocytes into adipocytes (6, 25) could be indicative of the 
coexistence of opposing growth and differentiation signals triggered by Mmps. Some family members such as 
Mmp2 and Mmp9 could remodel the extracellular matrix of adipogenic cells to facilitate the adipogenic process, 
whereas Mmp19 and other related enzymes could function in an opposite manner, slowing down or blocking this 
process. Alternatively, Mmp19 could regulate the bioavailability of adipocyte growth factors sequestered as 
inactive molecules in the matrix or blocked by interaction with their binding proteins. The recent finding that 
Mmp19 cleaves in vitro IGFBP3 (34) suggests that this protease could control the activity of insulin-like growth 
factors in adipose tissue and contribute to the modulation of adipocyte growth. Nevertheless, we did not observe 
variations in the molecular forms of the different components of the IGFBP system when we compared mutant 
and wild-type liver extracts by means of a Western ligand blot (data not shown), suggesting that these factors are 
not major in vivo substrates for this enzyme. Further studies now in progress will be required to identify the 
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specific substrates mediating the observed inhibitory function of Mmp19 during adipogenesis. 
FIG. 5: Skin tumorigenesis in Mmp19-/- and wild-type mice. (A) Percentage of flanks with tumor of Mmp19+/+ 
(♦) or Mmp19-/- (■) male mice injected with 100 µg of MCA; (B) histopathologic analysis of skin tumors 
generated in wild-type and Mmp19-/- male mice. 
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FIG. 6: Capillary outgrowth from mouse aortic rings of Mmp19-/- and wild-type mice. (A) Segments of mouse 
thoracic aortas from Mmp19+/+ and Mmp19-/- mice; (B) quantification in the aortic ring assay of the number of 
microvessels, the number of branchings, and the length of the vessels of Mmp19-/- and wild-type mice. 
 
The dispensability of Mmp19 during adult mouse development has also facilitated the analysis of cancer 
susceptibility in Mmp19-null mice, an aspect of growing interest after the finding of dual and important roles of 
these enzymes in tumor progression (2, 8,11,12, 30). Our studies with Mmp19-/- mice have shown that, after a 
typical MCA-induced chemical carcinogenesis protocol, these mutant mice develop fewer fibrosarcomas and 
with a longer latency period than wild-type litter-mates. Therefore, and similar to the situation previously 
described for most MMP family members, these in vivo experiments indicate that Mmp19 facilitates tumor 
progression. The role of Mmp19 in promoting cancer progression could be due to their ability to degrade a 
variety of extracellular matrix and basement membrane components, such as type IV collagen, fibronectin, 
tenascin-C, laminin, or nidogen, thereby facilitating the generation of a microenvironment permissive for tumor 
cell growth. However, recent studies have shown that the role of MMPs in cancer progression is much more 
complex than that derived from their direct degradative action on extracellular matrix components (11, 12). 
These additional functions mediated by MMPs include activation of growth factors, suppression of tumor cell 
apoptosis, release of angiogenic factors, or destruction of chemokine gradients generated by the host immune 
response. Accordingly, proteolytic processing of some of these bioactive molecules by Mmp19 could also 
contribute to the formation of the stromal environment necessary to promote malignant transformation and/or 
tumor growth in early stages of cancer. Because Mmp19 has been previously reported to be produced by 
endothelial cells and to possess angiogenic properties (18), we evaluated the hypothesis that the Mmp19 role in 
tumor progression could be linked to its proangiogenic functions. However, the ex vivo angiogenic potential of 
microvessels from aortic rings was not affected by Mmp19 deficiency, indicating that this process does not 
appear to be an important factor in the altered cancer susceptibility caused by the loss of this protease in Mmp19-
/- mice. Therefore, and similar to the case of the nutritionally induced obesity observed in Mmp19-null mice, 
further studies will be required to identify the mechanisms underlying the stimulatory action of Mmp19 in tumor 
progression. 
In summary, the generation of mutant mice deficient in Mmp19 has identified new in vivo roles for this 
proteolytic enzyme and provided a new model to study the relevance of protease-mediated processes taking 
place in adipogenesis or during tumor progression. Hopefully, these studies could contribute to the development 
of better therapeutic strategies for two major and growing medical problems: obesity and cancer. 
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